Deri Drianne Stiles, Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1628 Oklahoma Ave, Trenton, MO 64683 Phone: 660-359-4600 |
Kelli R Walker, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1628 Oklahoma Ave, Trenton, MO 64683 Phone: 660-359-4600 Fax: 660-359-4286 |
Mr. Lloyd Alan Hubbard, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1628 Oklahoma Ave, Trenton, MO 64683 Phone: 660-359-4600 Fax: 660-359-4286 |
Mindy Foster, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1628 Oklahoma Ave, Trenton, MO 64683 Phone: 660-359-4600 Fax: 660-359-4286 |
Katherine I Houghton, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 1628 Oklahoma Ave, Trenton, MO 64683 Phone: 660-359-4600 Fax: 660-359-4286 |
News Archive
In a study recently published on the bioRxiv preprint server, researchers attempted to further increase the scope of previous studies in examining SARS-CoV-2 infection of human CNS resident cells.
Everybody grieves the death of a loved one, and the process helps most mourners adjust to their loss. "Charlie Brown was right," said Christopher Layne, a psychologist and researcher at the Semel Institute for Neuroscience and Human Behavior at UCLA. "There is good grief." But for some people, bereavement becomes a problem in itself, prolonging suffering and impairing functioning. For grieving children and adolescents persistent complex bereavement disorder can derail social and academic development at a time when children and adolescents need to master skills and form aspirations to succeed later in life.
Kaiser Health News provides a fresh take on health policy developments with "Fancy Footwear?" by Steve Kelley.
In experiments with isolated cystic fibrosis lung cells, University of Alabama at Birmingham researchers and colleagues from two other institutions have partially restored the lost function of those cells.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it has officially accepted the filing of the Biologics License Application for ocriplasmin intravitreal injection, 2.5 mg/ml and granted it Priority Review.
› Verified 1 days ago